信邦製藥(002390.SZ):與嘉興行健共同合作研究開發新型冠狀病毒肺炎酶免(ELISA)檢測試劑盒
格隆匯2月6日丨信邦製藥(002390.SZ)公佈,公司全資子公司中肽生化有限公司(“中肽生化” 或“乙方”)以及康永生物技術有限公司(“康永生物”或“乙方”)近日與嘉興行健生物科技有限公司(“嘉興行健”或“甲方”)簽訂了《合作協議》。
雙方共同合作研究開發新型冠狀病毒肺炎酶免(ELISA)檢測試劑盒,研發成果雙方共享。
1、甲方負責肽鏈的設計以及進行新型冠狀病毒肺炎免疫檢測試劑盒的研發、注檢、臨牀驗證、註冊申報等相關事宜並進行量化生產;
2、乙方負責肽鏈的偶聯合成以及協助甲方進行新型冠狀病毒肺炎免疫檢測試劑盒的臨牀驗證,註冊申報並進行量化生產;
3、合作期限暫定為三年;
4、試劑盒研發存在一定的風險,研發結果如未能達到預期目標,雙方協商終止本協議。如果疫情得到控制,繼續研發本項目沒有社會意義,雙方協商終止本協議。
全資子公司中肽生化是國際知名的一體化多肽CRO/CDMO供應商,具有豐富多肽設計、研發、生產能力;全資子公司康永生物在疾病的快速診斷方面具有非常成熟的報批、生產及銷售經驗,是國內IVD的領先者。嘉興行健是國際知名的酶聯免疫法及國際創新型的磁微粒-吖啶酯全自動化學發光法的領導者,其自主研發、生產的體外診斷試劑及配套的磁微粒-吖啶酯全自動化學發光平台,屬於高端新型科學技術,配套該平台所檢測的試劑盒,多為國內獨家產品,且為國內亟需填補的IVD空白項目。值此非常時刻,中肽生化,嘉興行健,康永生物強強聯合,加快開發新型冠狀病毒快速、準確診斷的進度,滿足對新型冠狀病毒大量、快速、準確檢測的需求,為疫情的有效控制提供高效的篩查方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.